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Objective: Ischemia-reperfusion injury remains a major cause of mortality and
morbidity in clinical lung transplantation. Interaction of activated leukocytes with
injured graft endothelial cells participates in the development of ischemia-reperfu-
sion injury. We sought to determine if modification of the reperfusate (with
depletion of leukocytes and alteration of its composition) would decrease the
incidence of ischemia-reperfusion injury in human lung transplantation when com-
pared with whole blood reperfusion in a historical group of patients.
Methods: Between June 1999 and July 2001, 23 adult patients undergoing lung
transplantation consented to modified reperfusion. After implantation, a catheter was
inserted into the main or individual pulmonary arteries, and modified reperfusate was
administered at a pressure less than 20 mm Hg. The modified reperfusate was depleted
of leukocytes, supplemented with nitroglycerin, adjusted for pH and calcium level, and
enriched with aspartate, glutamate, and dextrose. After 10 minutes of modified reper-
fusion, the removal of pulmonary artery clamp or weaning of cardiopulmonary bypass
was performed per usual protocol. Age- and diagnosis-matched historical patients
served as the control group. Ischemia-reperfusion injury was defined as PaO2/FIO2 150
with diffuse infiltrate on the radiograph in absence of other causes.
Results: There was no difference in donor age or oxygenation indices, recipient age,
the number of patients requiring cardiopulmonary bypass, ischemia time, and
recipient oxygenation indices between the modified reperfusate group and the
control group. However, none of the patients in the modified reperfusate group
developed ischemia-reperfusion injury in contrast to 5 patients in the control group
(P .05). The early survival in the modified reperfusate group was 96% versus 81%
in the control group (P  NS).
Conclusion: This study suggests that modification of the reperfusate content decreases
the incidence of ischemia-reperfusion injury in human lung transplantation when com-
pared with whole blood reperfusion in a historical group of patients. Modified reperfu-
sate may allow acceptance of marginal lungs and expansion of the donor pool.
Despite advances in donor management and preservation tech-niques, ischemia-reperfusion injury (IRI) is estimated to occur in15% to 20% of lung transplant recipients.1,2 It is characterized bypatchy pulmonary infiltrates, widening of alveolar-arterial PO2gradient, and diminished pulmonary compliance, in the absenceof other potential causes. The treatment for this phenomenon in
lung transplantation remains largely supportive. Inhaled NO may be beneficial in
lung transplant recipients with IRI3; however, prophylactic administration of NO
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does not prevent this complication.4 The mortality asso-
ciated with IRI among lung transplant recipients is esti-
mated to be 40% to 60%.1,2 Additionally, the survivors
have a protracted recovery course and are often left with
residual impairment in lung function.1 Thus, IRI remains
a frequent cause of mortality and morbidity in lung trans-
plantation.
The molecular mechanisms underlying IRI involve the
complement system, reactive oxygen species, leukocytes,
and endothelium. The complement system, activated by
surgical stress and reperfusion of the ischemic organ, stim-
ulates proinflammatory mediators such as tumor necrosis
factor-alpha (TNF-), interleukin (IL)-1, and IL-6.5 These
mediators promote vascular permeability, activation of leu-
kocytes, and up-regulation of adhesion molecules on endo-
thelium.5 Reestablishment of blood flow to the ischemic
graft also stimulates production of reactive oxygen species
(ROS), which can damage cellular membranes via lipid
peroxidation and prime endothelial cells for leukocyte in-
teraction.6
Although the burst of ROS jump-starts the process, the
leukocyte–endothelial interaction is responsible for con-
tinuing the injury. Leukocytes, in particular neutrophils,
activated by complement and attracted to the endothelium
by the increased expression of adhesion molecules, begin
the process of adherence and transmigration.7,8 As the ac-
tivated neutrophils migrate through the endothelial barrier,
they degranulate, releasing proteases, collagenases, lipoxy-
genases, and myeloperoxidases.9 These toxins disrupt the
integrity of the endothelium and parenchymal tissue, lead-
ing to edema, thrombosis, and ultimately ischemia of the
tissue and cell death.
Given the importance of interactions between activated
leukocytes and graft endothelial cells in the development of
IRI, we hypothesized that a modified reperfusion protocol
that removes the leukocytes and resuscitates endothelial
cells via addition of nutrients will attenuate IRI.
Methods
Patient Population
Between June 1999 and July 2001, 23 adult patients undergoing
lung transplantation gave informed consent for modified reperfu-
sion and were prospectively enrolled into this study. The recipient
diagnoses were: obstructive lung disease (n  14), restrictive lung
disease (n  6), pulmonary vascular disease (n  1), and septic
lung disease (n  2). Twenty-three lung transplant recipients
matched for diagnosis and age (5 years) immediately preceding
this study (September 1997 to June 1999) were used as historical
controls. In this group, whole blood reperfusion was administered
at a pressure less than 20 mm Hg for the first 10 minutes.
Allograft Harvest and Implantation
Donor lungs were harvested using the previously described tech-
nique.10 Donor lung pulmonary artery beds were pretreated with
500 g of prostaglandin E1, followed by administration of 4 L of
modified Euro-Collins solution under a perfusion pressure not
exceeding 20 mm Hg. All allografts were procured in inflation
with tidal volume of approximately 10 mL/kg with an FIO2 of 1.0.
Methylprednisolone (500 mg) was given to all recipients preoper-
atively. Allograft implantation was performed according to the
previously described technique.11 All double lung transplant pro-
cedures in this study were performed on cardiopulmonary bypass.
The allograft ischemia time for this group of patients refers to the
time that both lung allografts were reperfused (with whole blood or
modified reperfusate).
Modified Reperfusion
Following implantation of right or left single lung allografts (off
cardiopulmonary bypass), a cannula was inserted into right atrium
or descending thoracic aorta, respectively. The recipient blood was
removed, depleted of leukocytes via Leukofilter (leukoGuard
BC1B, Pall Biomedical Products, East Hills, NY), and then mixed
with the modified reperfusion solution in a 1:4 ratio via a roller
pump (Table 1). Clinical and experimental studies have demon-
strated that this leukofilter can remove in excess of 70% of white
blood cells from up to 5.3 L of blood per minute.12,13 The modified
reperfusate was then administered through a DLP retrograde car-
dioplegia cannula (Minneapolis, Minn) that had been inserted into
the clamped pulmonary artery via the suture line (Figure 1). The
modified reperfusion flow rate was adjusted to maintain the reper-
fusion pressure at 20 mm Hg; the reperfusion pressure was
continuously monitored through the side port of the DLP retro-
grade cardioplegia cannula. The effluent during the first 3 minutes
of reperfusion was collected by pump suckers (in patients under-
going lung transplantation on cardiopulmonary bypass) or by cell
saver system (in patients undergoing lung transplantation without
cardiopulmonary bypass). After 3 minutes, the modified reperfu-
sion solution was stopped and leukocyte-depleted blood was con-
tinued for an additional 7 minutes. The time intervals of the
modified reperfusion protocol were based on prior similar studies
in heart transplantation.14 After the initial 3 minutes of reperfusion
and adequate deairing of the allograft, the left atrial clamp was
removed to allow return of the leukocyte-depleted blood into the
recipient’s circulation. The flow rates during the reperfusion phase
ranged from 200 to 500 mL per lung allograft.
In patients undergoing single lung transplant on cardiopulmo-
nary bypass, the modified pump blood was used to reperfuse the
allograft. In patients undergoing double lung transplantation on
cardiopulmonary bypass, the modified reperfusate was adminis-
tered into the clamped main pulmonary artery in a similar fashion
(Figure 2). The reperfusion pressure was measured with a needle
in the distal main pulmonary artery. Following 10 minutes of
modified reperfusion, the removal of pulmonary artery (PA) clamp
or weaning off cardiopulmonary bypass was performed per usual
protocol.
Postoperative Care
All patients were mechanically ventilated in a pressure-controlled
mode with settings adjusted to maintain PaO2  90 mm Hg.
Positive end expiratory pressure of 3 to 10 mm Hg was used to
optimize oxygenation and hemodynamics. All of the patients in the
control group and the first 5 patients in the modified reperfusate
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group were treated with equine anti-thymocyte globulin (ATGam,
Pharmacia, Peapack, NJ), followed by cyclosporine, azathioprine,
and prednisone. In January 2001, the immunosuppression regimen
was changed to induction therapy with rabbit anti-thymocyte glob-
ulin (Thymoglobulin, SangStat, Fremont, Calif), followed by ta-
crolimus, mycophenolate mofetil, and prednisone. The remaining
patients in the modified reperfusate group were treated with this
protocol.
Definition of Terms
Acute cellular rejection was defined as histologic grade A2 or
higher on lung biopsy. In some patients who had not undergone
lung biopsy, the diagnosis was made by constellation of clinical
findings consistent with rejection and reversal of clinical findings
with steroid bolus. Criteria for diagnosis of IRI were (1) hypox-
emia characterized by PaO2/FIO2  150 and (2) radiographic
evidence of diffuse alveolar infiltrates in the absence of other
potential causes. Early deaths were defined as deaths within 30
days of the operation or during the same hospitalization period.
Informed Consent
The protocol for modified reperfusion in lung transplantation was
reviewed and approved by the Human Subjects Protection Com-
mittee at UCLA.
TABLE 1. Composition of modified reperfusate solution
Solution
Volume
added (mL) Component modified Final concentration*
THAM (0.3 mol/L) 225 pH pH 7.5–7.6
CPD 225 Ca2 0.2–0.3 mmol/L
Aspartate/glutamate
(0.46 mol/L)
250 Nutrients 13 mmol/L
D5W 235 Osmolarity 380–400 mOsm
D50 40 Glucose 400 mg/dL
Mg SO4 (4 mEq/mL) 24 Mg
2 10–12 mEq/L
Nitroglycerin (5 mg/mL) 1 Vasodilator 5 mg/mL
THAM, Tromethamine; CPD, citrate-phosphate-dextrose.
*After being mixed with blood in a 4:1 ratio.
Figure 1. Schematic presentation of the technique of modified
reperfusion in right lung transplantation without cardiopulmonary
bypass. The recipient blood is drawn from the right atrial append-
age, modified, and then administered into the clamped pulmonary
artery of newly transplanted lung. After 3 minutes of reperfusion,
the clamp from pulmonary veins is removed to allow the return of
effluent into the recipient’s left atrium.
Figure 2. In patients undergoing double lung transplantation on
cardiopulmonary bypass, the cardiotomy reservoir blood is mod-
ified and then administered into the main pulmonary artery. After
3 minutes of reperfusion, the clamps from the pulmonary veins are
removed to allow return of effluent into the left atrium. After 10
minutes of modified reperfusion, the weaning off cardiopulmo-
nary bypass is performed per routine protocol.
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Statistical Analysis
All data measurements are presented as the means  standard
deviations. Comparison of the mean values was performed by
using repeated measures analysis of variance. Chi-square with 1
degree of freedom was used to compare the episodes of rejection
and infection between the modified reperfusate and the control
group.
Results
Patient Characteristics
There was no significant difference in donor age, donor
oxygenation level, recipient age, or the number of patients
undergoing lung transplantation on cardiopulmonary bypass
between the modified reperfusate group and the control
group (Table 2). Three patients in the modified reperfusate
group required intracardiac procedures in addition to lung
transplantation: mitral and tricuspid valve repair (n 1) and
tricuspid valve repair and repair of patent foramen ovale (n
 2). The allograft cold ischemia time was also similar in
the two groups (Table 2).
Patient Outcome
There were no intraoperative technical complications asso-
ciated with the modified reperfusion protocol. Two patients
in the modified reperfusate group developed acute renal
failure due to hemolysis associated with high flows through
the leukocyte filters. These 2 patients had not required
cardiopulmonary bypass for their lung transplant proce-
dures, and other causes of hemolysis were excluded. The
leukocyte filters have subsequently been changed to high-
flow filters.
There was no difference in the mean oxygenation indices
at 1 and 6 hours posttransplantation or the duration of
mechanical ventilation between the modified reperfusate
group and the control group (Table 2). Furthermore, the
mean initial white blood cell counts (13.6  6.9 vs 14.3 
5.1, P  NS), the mean initial platelet counts (203  67 vs
191  71, P  NS), and the mean number of transfused red
blood cell units in the first 24 hours after transplantation (2
 2.7 vs 1 2.8, P NS) were also similar in the modified
reperfusate and the control groups. However, the mean
number of days in intensive care was lower in the modified
reperfusate group when compared with the control group
(Table 2). We did not detect any difference in the cumula-
tive incidence of infection (pneumonia, urinary tract infec-
tion, and sepsis; 0.014  0.004 vs 0.011  0.004 episodes/
patient · days, P NS) or acute cellular rejection in the first
6 months after transplantation (0.009  0.003 vs 0.008 
0.004 episodes/patient · days, P  NS) between the modi-
fied reperfusate and the control groups. None of the patients
in the modified reperfusate group developed IRI, in contrast
to 5 patients in the control group (22%) (Table 2). And
finally, the early survival was 96% in the modified reper-
fusate group compared with 81% in the control group (P 
NS).
There was 1 early death in the modified reperfusate
group due to disseminated intravascular coagulation and
multisystem organ failure. The modified reperfusate in this
patient was delivered via a low-flow filter; however, the
hemolysis workup (free hemoglobin and haptoglobin level)
immediately after reperfusion was negative. There were 4
early deaths in the control group; one patient, who had not
developed IRI, died of aspiration pneumonia on postopera-
tive day 32. The other 3 deaths occurred in patients with IRI
(2 due to nosocomial pneumonia and respiratory failure and
1 due to sepsis of pulmonary versus abdominal source).
As noted above, 5 patients in the control group devel-
oped IRI. The diagnoses in this cohort were obstructive lung
disease (n  2) and restrictive lung disease (n  3). These
patients were treated with standard supportive care as well
as inhaled NO. The range of intensive care and hospital stay
in this subset of patients was 15 to 143 days and 28 to 143
days, respectively. The in-hospital mortality in the cohort of
patients with IRI was 60% (3/5).
Discussion
This study demonstrates that modification of the reperfusate
by leukodepletion and alteration of its composition de-
creases the incidence of IRI when compared with whole
blood reperfusion in human lung transplantation. The ben-
eficial effects of the modified reperfusate may be due to (1)
reduction in leukocyte-mediated injury, (2) resuscitation of
allograft vessel wall cells via the changes in composition of
the reperfusate, or (3) other factors. Neutrophils are known
to play a critical role in the inflammatory cascade that
follows the reperfusion of an ischemic organ. Neutrophils
can cause tissue injury via (1) elaboration of elastases and
TABLE 2. Perioperative characteristics and short-term out-
come of the modified reperfusate and the control groups
Modified
reperfusate
group
Control
group
Donor age 32 14 26 13
Donor PaO2/FIO2 on 100% 440 93 497 103
Recipient mean pulmonary artery
pressure (mm Hg)
31 12 28 9
Patients requiring CPB 8 6
Ischemia time (min) 288 78 205 39
PaO2/FIO2 at 1 hour 272 112 223 96
PaO2/FIO2 at 6 hours 314 138 267 100
Mean hours on ventilator 72 190 418 956
Mean days in ICU* 6 6 22 39
Incidence of IRI* 0 5/23
Early survival 22/23 (96%) 19/23 (81%)
CPB, Cardiopulmonary bypass; ICU, intensive care unit; IRI, ischemia-
reperfusion injury.
*P  .05.
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other proteases9; (2) direct release of inflammatory cytokine
such as TNF-, IL-1, IL-6, and IL-815; and (3) capillary
plugging leading to no-reflow phenomenon, further exacer-
bating local ischemia.16 The importance of neutrophils in
IRI is further substantiated by multiple experimental studies
utilizing leukocyte filters or monoclonal antibodies directed
against adhesion molecules on leukocytes and endothelial
cells.17-19 More recently, lymphocytes have also been
shown to directly participate in the development of IRI.20
Hence, mechanical removal of leukocytes during the initial
critical phase of reperfusion may be responsible, at least in
part, for the beneficial effect of the current protocol.
Aside from leukocytes, the composition of the initial
reperfusate can also affect the functional recovery of isch-
emic organ. Alteration of the composition of the reperfusion
solution has been shown to prevent reperfusion injury in
myocardial ischemia.21 The content of the initial reperfusate
in this study was based on similar theoretical grounds and
prior experimental studies in lung transplantation.12,22 Cal-
cium influx into the cells was prevented by addition of
citrate and magnesium to the reperfusate; tissue edema was
minimized by adding agents with high oncotic pressure; and
acidosis was buffered by addition of tromethamine. Cellular
resuscitation was facilitated by enriching the solution with
aspartate and glutamate, which have been shown to improve
functional recovery of myocytes after a brief period of
ischemia.21 In addition, nitroglycerin was added to ensure
the homogeneous delivery of the reperfusate. It is important
to note that other factors such as hemodilution may also
contribute to the beneficial effects of the modified reperfu-
sate.23 With better understanding of molecular mechanisms
of IRI in lung transplantation and development of more
effective agents to counteract the inflammatory process, the
content of initial reperfusate is likely to change and result in
further protection.
This report, to our knowledge, is the first study compar-
ing modified reperfusion with whole blood reperfusion in
human lung transplantation. The hypothesis leading to this
study was based on the pioneering work of several
groups.21,22 Furthermore, the technique of modified reper-
fusion has been described previously in 5 patients undergo-
ing lung transplantation.24 Although the content of reperfu-
sate is likely to change in the future, the concept of
controlling the composition and condition of initial reper-
fusate remains the principal message of this report. The
ideal duration and pressure of the initial reperfusate admin-
istration in lung transplantation is unknown. In an experi-
mental model, Bhabra and colleagues25 have shown that
controlling the reperfusate condition for less than 10 min-
utes was not as effective and that extending beyond 30
minutes did not confer any additional benefit. In contrast, in
myocardial ischemia, 20 minutes of controlled reperfusion
has been shown to be superior to 10 minutes.21 Together,
these reports highlight the importance of the initial phase of
reperfusion in mediating tissue injury, especially the first 10
minutes. Experimental studies have also shown that lower-
ing the reperfusion pressure to 20 to 30 mm Hg decreases
the reperfusion injury and improves allograft function.26 It
is not known if further lowering of PA pressure can confer
any additional benefit while ensuring homogeneous distri-
bution of the reperfusate. Additional experimental studies
are needed to define the ideal duration and pressure of the
reperfusate, as well as the optimal conditions of ventilating
the allograft (FIO2, airway pressure, etc).
A safety concern associated with leukocyte depletion in
immunosuppressed transplant recipients is the risk of infec-
tion. In this study, the initial white blood cell count was
similar in the modified reperfusate and the control groups.
Moreover, the cumulative incidence of infections in the first
30 days posttransplantation was also similar. Another safety
concern with the use of leukofilters is thrombocytopenia. In
addition to leukodepletion, currently available filters also
remove platelets and may promote perioperative bleeding.
In this study, we could not detect a significant difference in
the initial platelet count or the incidence of perioperative
bleeding in the modified reperfusate versus the control
group. Thus, this study suggests that administration of mod-
ified reperfusate in human lung transplantation is associated
with acceptable safety profile. The limitations of this study
include the small number of patients in each group and the
historical/noncontemporaneous comparison group.
Bronchiolitis obliterans syndrome (BOS) remains the
leading cause of late death among lung transplantation
recipients.27 In addition to alloantigen-dependent mecha-
nisms, alloantigen-independent factors such as the impact of
donor brain death on the allograft and ischemia-reperfusion
injury may participate in the development of BOS.28 In fact,
in kidney transplantation, delayed early allograft function, a
manifestation of IRI, has been associated with late graft loss
due to chronic rejection.29 Hence, there is emerging data
that minimization of allograft injury in the perioperative
period may not only impact early graft function but may
also favorably affect long-term graft function. Future com-
parison of the incidence of BOS in the cohort of patients
enrolled in this study may provide insight into the impact of
modified reperfusate versus whole blood reperfusate on
long-term allograft function.
In conclusion, this study suggests that modification of
reperfusate by leukodepletion and alteration of its compo-
sition decreases the incidence of reperfusion injury in hu-
man lung transplantation. A prospective randomized trial of
modified reperfusion versus whole blood reperfusion is
necessary to define the role of this technique in lung trans-
plantation. Strategies that minimize the risk of IRI may not
only improve patient survival but may also allow accep-
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tance of nonstandard lungs and expansion of the donor lung
pool.
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